Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Blankenstein

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
World Journal of Urology|July 6, 2005
Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cellsBernhard Frankenberger, Sybille Regn, Christiane Geiger, et al.
Cytotherapy|May 7, 2022
Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapyMaría Fernanda Lammoglia Cobo, Carlotta Welters, Leonie Rosenberger, et al.
Cancers|April 3, 2021
CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-StimulusAna Textor, Laura Grunewald, Kathleen Anders, et al.
Nature Immunology|April 19, 2024
Author Correction: IFNγ binding to extracellular matrix prevents fatal systemic toxicityJosephine Kemna, Evelyne Gout, Leon Daniau, et al.
Nature Immunology|February 2, 2023
IFNγ binding to extracellular matrix prevents fatal systemic toxicityJosephine Kemna, Evelyne Gout, Leon Daniau, et al.
Molecular Medicine (Cambridge, Mass.)|December 28, 2012
High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccinationHeike Pohla, Alexander Buchner, Birgit Stadlbauer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 2, 2007
T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imagingRalf Agger, Mikkel S Petersen, Charlotte C Petersen, et al.
Cancer Research|July 19, 2017
CTLA4 Promotes Tyk2-STAT3-Dependent B-cell OncogenicityAndreas Herrmann, Christoph Lahtz, Toshikage Nagao, et al.
Journal for Immunotherapy of Cancer|May 2, 2025
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoireLeonie Rosenberger, Leo Hansmann, Vasiliki Anastasopoulou, et al.
Haematologica|September 16, 2024
A phase I study of MAGE-A1-targeted T1367 T-cell receptorbased cell therapy in patients with advanced multiple myelomaJosefine Krüger, Matthias Obenaus, Igor Wolfgang Blau, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
World Journal of Urology|July 6, 2005
Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cellsBernhard Frankenberger, Sybille Regn, Christiane Geiger, et al.
Cytotherapy|May 7, 2022
Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapyMaría Fernanda Lammoglia Cobo, Carlotta Welters, Leonie Rosenberger, et al.
Cancers|April 3, 2021
CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-StimulusAna Textor, Laura Grunewald, Kathleen Anders, et al.
Nature Immunology|April 19, 2024
Author Correction: IFNγ binding to extracellular matrix prevents fatal systemic toxicityJosephine Kemna, Evelyne Gout, Leon Daniau, et al.
Nature Immunology|February 2, 2023
IFNγ binding to extracellular matrix prevents fatal systemic toxicityJosephine Kemna, Evelyne Gout, Leon Daniau, et al.
Molecular Medicine (Cambridge, Mass.)|December 28, 2012
High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccinationHeike Pohla, Alexander Buchner, Birgit Stadlbauer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 2, 2007
T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imagingRalf Agger, Mikkel S Petersen, Charlotte C Petersen, et al.
Cancer Research|July 19, 2017
CTLA4 Promotes Tyk2-STAT3-Dependent B-cell OncogenicityAndreas Herrmann, Christoph Lahtz, Toshikage Nagao, et al.
Journal for Immunotherapy of Cancer|May 2, 2025
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoireLeonie Rosenberger, Leo Hansmann, Vasiliki Anastasopoulou, et al.
Haematologica|September 16, 2024
A phase I study of MAGE-A1-targeted T1367 T-cell receptorbased cell therapy in patients with advanced multiple myelomaJosefine Krüger, Matthias Obenaus, Igor Wolfgang Blau, et al.
Pageof 14